We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+39.93%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$764M
AUM Growth
+$105M
Cap. Flow
-$30.5M
Cap. Flow %
-4%
Top 10 Hldgs %
84.2%
Holding
19
New
–
Increased
2
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
AGRX
Agile Therapeutics
AGRX
+$7.12M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$5.57M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$19.8M
2
CTLT
CATALENT, INC.
CTLT
+$18.9M
3
LITS
Lite Strategy Inc
LITS
+$4.53M

Sector Composition

Rank Sector Weight
1 Healthcare 84.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
1
DELISTED
Esperion Therapeutics
ESPR
$190M 24.9%
2,054,594
– –
CEMP
2
DELISTED
Cempra, Inc.
CEMP
$113M 14.79%
3,293,060
– –
ZLTQ
3
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$80.1M 10.48%
2,597,742
– –
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$43M 5.63%
3,452,493
– –
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
$41.9M 5.48%
379,928
+47,500
+14% +$5.57M
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
$39.2M 5.12%
505
– –
CMRX
7
DELISTED
Chimerix, Inc.
CMRX
$38.6M 5.05%
1,022,943
-500,000
-33% -$19.8M
ADMA icon
8
ADMA Biologics
ADMA
$1.94B
$35.4M 4.63%
3,608,171
– –
CTLT
9
DELISTED
CATALENT, INC.
CTLT
$34.5M 4.51%
1,106,729
-654,496
-37% -$18.9M
AGRX
10
DELISTED
Agile Therapeutics
AGRX
$27.7M 3.62%
1,492
+406
+37% +$7.12M
ASXC
11
DELISTED
Asensus Surgical, Inc.
ASXC
$24.4M 3.2%
641,217
– –
PTX
12
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$21.5M 2.81%
201,000
– –
PRTK
13
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$21.3M 2.79%
682,680
– –
SRNE
14
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$20.4M 2.67%
1,763,500
– –
DERM
15
DELISTED
Dermira, Inc.
DERM
$16.9M 2.21%
1,102,046
– –
XENT
16
DELISTED
Intersect ENT, Inc
XENT
$9.04M 1.18%
350,000
– –
ROKA
17
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$3.59M 0.47%
112,242
– –
EVAR
18
DELISTED
Lombard Medical, Inc.
EVAR
$3.57M 0.47%
886,363
– –
LITS
19
Lite Strategy Inc
LITS
$35.4M
– –
-50,590
Closed -$4.53M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Aisling Capital held 19 positions worth $764M, up 16% from $660M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Aisling Capital withdrew a net $30.5M in Q1 2015, closing 1 position and reducing 2 holdings. Its most notable exit was Lite Strategy Inc, an estimated $4.53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier.

Against the trend, Aisling Capital added an estimated $7.12M to Agile Therapeutics.

  • Aisling Capital added most to Agile Therapeutics in Q1 2015, an estimated $7.12M increase.
  • Aisling Capital's biggest Q1 2015 reduction was Chimerix, Inc., cutting an estimated $19.8M.
  • Aisling Capital fully exited Lite Strategy Inc in Q1 2015, selling an estimated $4.53M.
  • Aisling Capital's ten largest holdings make up 84% of its $764M portfolio in Q1 2015.
  • Aisling Capital opened 0 new positions and closed 1 in Q1 2015.
  • Aisling Capital's portfolio value rose 16% quarter-over-quarter to $764M.

Based on Aisling Capital's 13F filing for Q1 2015, filed 11 May 2015.